Aktuellt
SENASTE
Redeye comments on yesterday’s news that the rights to Mesdopetam have been returned to IRLAB. Furthermore, as the company now has the communication rights, IRLAB also shared more data from the phase IIb trial of the drug candidate in PD-LIDs.
LÄS MER
